New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2013
09:13 EDTONCYOncolytics Biotech reports FY12 EPS (C$0.48), consensus (43c)
Reports FY12 Research and development expensed C$31.4M.
News For ONCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 5, 2015
06:33 EDTONCYOncolytics Biotech's Reolysin shows positive preclinical results in melanoma
Oncolytics Biotech announced an oral presentation by the company's research collaborators from a variety of melanoma models. They concluded that the combination of Reolysin and radiation therapy enhances cytotoxicity in those cell lines by increasing programmed cancer cell death, and that radiation therapy supports increased reovirus replication and suppresses the host cell's anti-viral defenses. This builds on a recent publication that demonstrated that Reolysin could act synergistically in combination with a new class of targeted agents to treat skin cancers with a specific mutation. The publication outlined how the combination of REolysin and BRAF inhibitors improved survival in mouse models compared to either agent alone.
March 3, 2015
06:34 EDTONCYOncolytics Biotech receives ODD from FDA for Reolysin
Oncolytics Biotech announced that the FDA has granted Orphan Drug Designation, or ODD, for its lead product candidate, Reolysin, for the treatment of primary peritoneal cancers. The designation was granted on the basis of the Company's December 2014 application for an Orphan Drug Designation encompassing ovarian, fallopian tube and primary peritoneal cancers which are generally treated as one indication. On February 11, the company announced that it had received Orphan Drug Designation for ovarian cancer and for cancers of the fallopian tube on March 2.
06:32 EDTONCYOncolytics Biotech receives Orphan Drug Designation for Reolisyn
Oncolytics Biotech announced that the FDA has granted Orphan Drug Designation for its lead product candidate, Reolisyn, for the treatment of primary peritoneal cancers. The designation was granted on the basis of the Company's December 2014 application for an Orphan Drug Designation encompassing ovarian, fallopian tube and primary peritoneal cancers which are generally treated as one indication.
March 2, 2015
06:38 EDTONCYOncolytics Biotech announces receipt of Orphan Drug Designatoin for REOLYSIN
Subscribe for More Information
06:37 EDTONCYOncolytics Biotech receives ODD from FDA for Reolysin
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use